Ultragenyx (RARE) | Stock Overview & Key Data
Ultragenyx Performance Comparison
Stock Range
Today's Range
Low: $29.50
High: $30.41
on August 22, 2025
52 Week Range
Low: $25.81
High: $60.37
on July 21, 2025
on September 16, 2024
All-Time High: $179.65 on December 21, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.9B
EPS
-5.48
P/E Ratio (TTM)
-4.73
Forward P/E
-5.83
P/B Ratio
18.93
PEG Ratio
0.21
Div. Yield
N/A
ROE
-180.44%
Beta
0.245
Debt to Equity
557.79
Financial Highlights
Profitability
Gross Margin
86.18%
Operating Margin
-64.80%
Profit Margin
-87.34%
Returns and Earnings
Return on Assets (TTM)
-21.59%
Return on Equity (TTM)
-180.44%
EBITDA
$-469.6M
Net Income (TTM)
$-532.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$6.60
Quarterly Revenue Growth (YoY)
13.20%
Quarterly Earnings Growth (YoY)
13.24%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ultragenyx RARE | 2.87B Mid-cap | 0.30% | 12.63% | -16.14% | -28.82% | -27.63% | -47.52% | -39.84% | -65.25% |
| Vertex VRTX | 101.31B Large-cap | 0.59% | -15.96% | -8.96% | -17.97% | -2.62% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 63.57B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| BridgeBio Pharma BBIO | 9.58B Mid-cap | -4.36% | 7.23% | 48.86% | 35.39% | 74.04% | 93.92% | 368.32% | 65.87% |
| Madrigal MDGL | 9.07B Mid-cap | 12.12% | 32.32% | 51.70% | 28.73% | 32.16% | 64.07% | 491.89% | 288.86% |
| Halozyme HALO | 8.38B Mid-cap | 6.76% | 24.82% | 33.62% | 22.77% | 49.59% | 14.51% | 78.26% | 152.53% |
Ownership & Short Interest
Insider Ownership
3.14%
Institutional Ownership
101.49%
Shares Short
8M
Short Ratio
2.59
Short % of Shares Outstanding
8.21%
Average 10-Day Volume
1M
Average 90-Day Volume
2M
Ultragenyx Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ultragenyx would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is RARE's 52-week high and low?
- In the last 52 weeks, Ultragenyx reached a high of $60.37 (on September 16, 2024) and a low of $25.81 (on July 21, 2025).
- What is the market cap and P/E ratio for RARE?
- Curious about Ultragenyx's size and valuation? Its market capitalization stands at 2.87B. When it comes to valuation, the P/E ratio (trailing twelve months) is -4.73, and the forward P/E (looking ahead) is -5.83.
- Does RARE pay dividends? If so, what's the yield?
- As for dividends, Ultragenyx isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ultragenyx's main competitors or similar companies to consider before investing?
When looking at Ultragenyx, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.31B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN63.57B Healthcare Biotechnology -50.84% -1.12% BridgeBio Pharma
BBIO9.58B Healthcare Biotechnology 93.92% 368.32% Madrigal
MDGL9.07B Healthcare Biotechnology 64.07% 491.89% Halozyme
HALO8.38B Healthcare Biotechnology 14.51% 78.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ultragenyx Pharmaceutical Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Ultragenyx's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -180.44%, the Debt to Equity ratio from the most recent quarter is 557.79, and its Gross Profit Margin stands at 86.18%.
- What is the recent revenue and earnings growth for RARE?
- Looking at Ultragenyx's growth, its revenue over the trailing twelve months (TTM) was $610M. Compared to the same quarter last year (YoY), quarterly revenue grew by 13.20%, and quarterly earnings saw a YoY growth of 13.24%.
- How much of RARE stock is held by insiders and institutions?
- Wondering who owns Ultragenyx stock? Company insiders (like executives and directors) hold about 3.14% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 101.49%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.